Charles River Laboratories International, Inc.

NYSE:CRL Stock Report

Market Cap: US$8.3b

Charles River Laboratories International Balance Sheet Health

Financial Health criteria checks 4/6

Charles River Laboratories International has a total shareholder equity of $3.8B and total debt of $2.3B, which brings its debt-to-equity ratio to 60.1%. Its total assets and total liabilities are $8.0B and $4.2B respectively. Charles River Laboratories International's EBIT is $598.0M making its interest coverage ratio 4.9. It has cash and short-term investments of $210.2M.

Key information

60.1%

Debt to equity ratio

US$2.30b

Debt

Interest coverage ratio4.9x
CashUS$210.17m
EquityUS$3.83b
Total liabilitiesUS$4.18b
Total assetsUS$8.00b

Recent financial health updates

Recent updates

Charles River Laboratories: Retained Earnings, ROE, And Debt Management Will Shape Its Future Amid Weak Demand

Feb 01

We Think Charles River Laboratories International (NYSE:CRL) Is Taking Some Risk With Its Debt

Jan 26
We Think Charles River Laboratories International (NYSE:CRL) Is Taking Some Risk With Its Debt

Charles River Labs: Near A Fundamental Trough, Growth  Should Reignite Again

Jan 17

What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Jan 10
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Is There Now An Opportunity In Charles River Laboratories International, Inc. (NYSE:CRL)?

Dec 11
Is There Now An Opportunity In Charles River Laboratories International, Inc. (NYSE:CRL)?

Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle

Nov 19

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

Oct 26
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Oct 11
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching

Sep 10
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching

US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Aug 10
US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)

Aug 10

Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt

Jul 26
Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)

Jul 11
Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)

Charles River Laboratories: Fair Valuation Against Fundamentals

May 31

What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

May 25
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?

Apr 27
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings

Apr 11
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings

Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Mar 27
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Feb 21
Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'

Feb 16

Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation

Nov 26

Charles River: Q3 Points To Ongoing Deterioration

Nov 09

Charles River Laboratories: Diving Into The Lab (Rating Upgrade)

Oct 06

Charles River Laboratories: Very Attractive After The Pullback

Jul 26

Financial Position Analysis

Short Term Liabilities: CRL's short term assets ($1.5B) exceed its short term liabilities ($1.0B).

Long Term Liabilities: CRL's short term assets ($1.5B) do not cover its long term liabilities ($3.2B).


Debt to Equity History and Analysis

Debt Level: CRL's net debt to equity ratio (54.6%) is considered high.

Reducing Debt: CRL's debt to equity ratio has reduced from 120.6% to 60.1% over the past 5 years.

Debt Coverage: CRL's debt is well covered by operating cash flow (34.6%).

Interest Coverage: CRL's interest payments on its debt are well covered by EBIT (4.9x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/05 08:55
End of Day Share Price 2025/02/05 00:00
Earnings2024/09/28
Annual Earnings2023/12/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Charles River Laboratories International, Inc. is covered by 46 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Gregory BolanAvondale Partners
Eric ColdwellBaird